홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
Heatmap
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
URGN
#2445
UroGen Pharma Ltd. Ordinary Shares
21.220
0
USD
+4.64%
부문:
헬스케어
베이스:
USD
수익 통화:
USD
일일 변동 비율
년간 변동
일일 변동
+4.64%
월간 변동
+12.69%
6달 변화
+11.68%
년간 변동율
+11.68%
이전 종가
20.280
0
Open
21.220
0
Bid
Ask
Low
21.220
0
High
21.220
0
양
100
마켓
주식
헬스케어
URGN
Open full chart
Financials
Overview
성명
Statistics
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
22.27 M
22.67 M
23.44 M
34.12 M
46.09 M
48.68 M
—
Valuation ratios
Enterprise value
348.49 M
171.21 M
244.66 M
522.55 M
441.4 M
1.15 B
3.31 B
Price to earnings ratio
—
—
-1.79
-4.29
-3.6
-7.34
-20.71
Price to sales ratio
—
—
3.52
6.45
5.86
11.93
37.73
Price to cash flow ratio
—
—
-2.25
-5.74
-4.72
-6.94
-23.5
Price to book ratio
—
—
-2.21
-6.73
-51.87
-10.68
24.82
EBITDA 비율에 대한 기업 가치
-2.75
-1.87
-2.86
-6.6
-4.05
-8.17
-23.78
Profitability ratios
Return on assets %
-1.05
-0.93
-0.81
-0.57
-0.44
-0.77
-0.73
Return on equity %
-1.33
-13.17
1.23
1.57
14.41
1.46
2.02
Return on invested capital %
-1 304.03
-2 060.7
-1 538.17
-1 158.23
-1 526.09
-1 244.1
-1 789.5
Gross margin %
91.45
89.27
101.4
107.87
104.67
103.07
415.45
Operating margin %
-1 074.15
-192.11
-141.35
-96.38
-124.28
-132.21
-604.15
EBITDA margin %
-1 074.29
-190.38
-154.79
-116.84
-139.98
-149.57
-679.23
Net margin %
-1 088.94
-230.67
-196.33
-150.36
-162.92
-162.53
-735.25
Liquidity ratios
Quick ratio
5.3
4.9
5.21
5.24
5.81
3.65
16.9
Current ratio
5.39
5.11
5.39
5.42
6.01
4.01
17.78
Inventory turnover
—
—
0.19
0
—
—
—
Asset turnover
0.07
0.4
0.44
0.43
0.34
0.39
0.45
Solvency ratios
Debt to assets ratio
—
—
0.72
0.55
0.43
0.62
2.37
Debt to equity ratio
—
—
-1.09
-1.51
-13.91
-1.17
-6.21
Long term debt to total assets ratio
—
—
0.72
0.55
0.43
0.61
2.35
Long term debt to total equity ratio
—
—
-1.09
-1.51
-13.83
-1.16
-6.16
Per share metrics
Operating cash flow per share
—
—
-3.84
-2.65
-2.26
-3.38
-3.4
EBIT per share
—
—
-3.84
-2.78
-2.55
-2.94
-2.96
EBITDA per share
—
—
-3.8
-2.76
-2.54
-2.94
-2.96
Total debt per share
—
—
4.28
3.42
2.86
2.57
10.31
Cash per share
—
—
4.38
4.91
5.64
2.5
12.77
Net current asset value per share
—
—
5.65
5.87
6.44
3.87
16.5
Tangible book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
Working capital per share
—
—
4.6
4.79
5.37
2.9
12.77
Book value per share
—
—
-3.92
-2.26
-0.21
-2.19
-7.53
뉴스
UroGen: ZUSDURI Poised To Replace TURBT Surgery As SOC In Certain Bladder Cancers
UroGen Pharma, 전략적 성장 및 혁신 발표
UroGen Pharma at TD Cowen Conference: Strategic Growth and Innovation
오펜하이머, Zusduri 판매 호조에 UroGen Pharma 목표가 34달러로 상향
Oppenheimer raises UroGen Pharma stock price target to $34 on Zusduri sales
오펜하이머, Zusduri 판매 호조에 UroGen Pharma 투자의견 유지
Oppenheimer reiterates UroGen Pharma stock rating on strong Zusduri sales
Earnings call transcript: UroGen Pharma Q4 2025 misses EPS and revenue forecasts
Palantir and AeroVironment among market cap stock movers on Monday
Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates
UroGen Pharma Q1 실적, 수익 에상치보다 저조
UroGen Pharma earnings missed by $0.06, revenue fell short of estimates